Abstract: The aim of this study was to examine histomorphologically how bisphosphonate (BP) injected before and after implant placement surgery affects the peri-implant bone in vitamin D-deficient animal model. This study used 60 six-week-old male Sprague-Dawley (SD) rats which were given a vitamin D-deficient diet. These experimental animals were divided into Group 1 (BP administration starting before implant placement), Group 2 (control group) and Group 3 (BP administration starting after implant placement). Threaded titanium implant was placed 0.50 mm mesial to the first molar. The samples were tissues from Groups 1 and 2 obtained at 1, 2, 4 and 8 weeks after implant placement and tissues from Group 3 obtained after the start of BP administration. Evaluation by light microscope and micro-CT imaging were performed. In Group 1, bone density around implants significantly increased as time progressed from after implant placement. In Group 3, bone density significantly decreased as the duration of bisphosphonate use increased. Group 1 had a significantly higher proportion of lacunae without osteocytes compared with Group 2 after implant placement. In Group 3, the proportion of these lacunae increased significantly from one to two weeks after the start of bisphosphonate administration. There were significantly higher proportions at 4 weeks and 8 weeks after the start of administration compared with 1 week after the start. This histological result suggests the need to exercise caution in using implant treatment on patients taking bisphosphonates and in administering bisphosphonates in patients after implant placement.
Introduction
Implant treatment achieves a highly functional restoration, and good prognosis can be expected. Therefore, it has rapidly become a widely used, effective treatment for missing teeth. Implant treatment is often performed in elderly patients who have a history of various systemic diseases. Thus, they are usually undergoing treatment for these diseases.
Bisphosphonates (BP) are used to treat bone metastasis and systemic bone diseases such as Paget disease and osteoporosis [1] [2] [3] [4] .
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) was first reported by Marx and Wang et al. in 2003 5,6) . It is known that tooth extraction can lead to BRONJ 7, 8) , and BRONJ related to implant treatment has also been reported 9, 10) . There is a tendency for multiple osteonecrosis to occur in myeloma patients and breast cancer patients with vitamin D-deficiency. Vitamin D deficiency can increase the risk for osteonecrosis of the jaw 11, 12) . Therefore, it is necessary to elucidate the effects of vitamin D deficiency and bisphosphonate administration on peri-implant bone to safely perform implant treatment. The aim of this study was to examine histomorphologically how bisphosphonate injected before and after implant placement surgery affects the peri-implant bone in vitamin D-deficient animal model.
Materials and Methods
This study used 60 six-week-old male Sprague-Dawley (SD) rats (weight: 180-210 g). These experimental animals were divided into 3 groups as will be described later.
Group 1 (bisphosphonate (BP) administration starting before implant placement)
The rats were given a vitamin D-deficient diet (Diet11: 0.47% Ca, 0.30% P; Japan-CLEA, Tokyo, Japan) beginning at 6 weeks old to obtain vitamin D-deficient rats. The rats were raised on 12-h light-12-h dark cycles. When the vitamin D-deficient diet was begun, the rats also began to receive administration of zoledronate (Zometa, Novartis Pharma, Tokyo, Japan). Zoledronate (4.0 mg) was diluted with 100 ml physiological saline, and the resulting solution was injected into the tail vein of each rat (dose: 35 g/ kg). The injection was performed once every 2 weeks 13) . The vitamin D-deficient diet and bisphosphonate administration were continued until the rats were sacrificed. When the rats were 9 weeks old, they were given local anesthesia with lidocaine hydrochloride (ORA Inj., Showa Yakuhin Kako, Tokyo, Japan) and inhalation general anesthesia with isoflurane (Forane, Abbott Japan, Tokyo, Japan). Implant placement surgery was performed according to the following method. An incision was made to the periosteum of the maxilla mesial to the first molar. A mucoperiosteal flap was reflected, and the bone surface was
exposed. An implant socket was prepared 0.50 mm mesial to the first molar using a drill 14) , and the socket was 1.0 mm in diameter and 2.0 mm in depth. Subsequently, a driver was used at low speed to place the experimental implant body (threaded titanium implant body with a diameter of 1.2 mm and length of 3.0 mm; Nanto Seimitsu, Shizuoka, Japan). The head of the implant body was left exposed to the oral environment. Absorbable sutures (VICRYL, Johnson and Johnson, New Brunswick, USA) were used to close the wound around the head of the implant.
At 1, 2, 4 and 8 weeks after implant placement, the rats were placed under general anesthesia and perfused-fixed with halfstrength Karnovsky's fixative (2.5% glutaraldehyde and 2% paraformaldehyde). Samples were collected that included the implant bodies.
Group 2 (control group)
Physiological saline instead of zoledronate was injected into the tail vein of each rat. Besides this change, the protocol of the experiment was the same as in Group 1.
Group 3 (BP administration starting after implant placement)
When the rats were 6 weeks old, the experimental implants were placed using the same surgical method as in Groups 1 and 2.
The implant was placed in the edentulous space in the maxilla mesial to first molar.
The rats were given a vitamin D-deficient diet (Diet11: 0.47% Ca, 0.30% P; Japan-CLEA, Tokyo, Japan) 4 weeks after implant placement (at 10 weeks old). The rats also began to receive administration of zoledronate (Zometa, Novartis Pharma, Tokyo, Japan). Zoledronate (4.0 mg) was diluted with 100 ml physiological saline, and the resulting solution was injected into the tail vein of each rat (dose: 35 g/kg). The injection was performed once every 2 weeks. The vitamin D-deficient diet and bisphosphonate administration were continued until the rats were sacrificed. At 1, 2, 4 and 8 weeks after the start of bisphosphonate administration (5, 6, 8 and 12 weeks after implant placement), samples were collected using the same method as in Group 1.
Evaluation of biomarkers of bone metabolism
When the rats were 6 and 9 weeks old, blood tests and urinalysis were performed in Group 2. An evaluation was performed on the changes in biomarkers of bone metabolism due to vitamin D deficiency (examined items: 25(OH)D, Ca, P, ALP, PTH, OC, TRACP-5b, DPD, Cre, and DPD/CRE).
Micro-CT imaging and evaluation
Bone density was measured in samples obtained at 1, 2 and 4 weeks after implant placement in Groups 1 and 2 and samples obtained at 1, 2 and 4 weeks after the start of BP administration for Group 3. CT images (SkyScan 1176, Bruker micro CT, Belgium) were taken of these samples and a phantom for QCT to calculate bone density. The imaging data were used for 3-dimensional image reconstruction (NRecon, Bruker micro CT, Belgium). Bone density was measured in the peri-implant area within 500 m from the implant surface (CT-An, Bruker micro CT, Belgium).
Preparation of light microscopy sections Decalcified tissue specimens
The samples were tissues from Groups 1 and 2 obtained at 1, 2, 4 and 8 weeks after implant placement and tissues from Group 3 obtained at 1, 2, 4 and 8 weeks after the start of BP administration. These samples were immersed in half-strength Karnovsky's fixative (2.5% glutaraldehyde and 2% paraformaldehyde) for 48 h and decalcified in 0.50M EDTA for 14 days. After decalcification, each implant body was carefully removed so that the interface was not disrupted, and the samples were embedded in paraffin.
The resulting paraffin blocks were sliced into 3.0 m-thick sections using a sliding microtome (Leica, Solms, Germany). The sections were stained with hematoxylin and eosin (H&E staining).
Tissue specimens stained with tartrate-resistant acid phosphatase (TRAP)
The same method as for the decalcified tissue specimens was used to prepare 3.0 m-thick sections for TRAP-staining. The sections were deparaffinized and washed with water. They were placed in the TRAP solution for 40 min. washed, and stained with hematoxylin for 5-6 seconds. The prepared sections were examined under a light microscope (BX51, Olympus Co.,Tokyo, Japan). Peri-implant bone was histomorphologically evaluated for each group using decalcified specimens (H&E staining). Evaluation of lacunae without osteocytes was performed in the region within 500 m of the boneimplant interface (calculation of proportion of lacunae without osteocytes).
Evaluation by light microscope and statistical analysis
Statistical analysis was performed by parametric t-test. Statistical significance was set at p<0.05. In TRAP-stained sections, the number, morphology, and distribution of TRAPpositive cells were examined.
Results figure, Group 1, H&E staining) : the peri-implant area in the marrow region was mostly covered with fibrous connective tissue. There was no area where the implant body contacted the bone. Severe inflammatory cell infiltration was observed. In addition, an isolated sequestrum was observed in the connective tissue (black frame). In the region distant from the implant body, the bone tissue was normal and lacunae without osteocytes were very scarce. Osteoclast-like cells were observed on the surface of the bone distant from the implant (black frame). (M: mesial side, D: distal side, O: oral cavity side, R: rhinal side) Magnified image of the area in the black frame (Lower image, Group 1, H&E staining): An isolated sequestrum was observed in the connective tissue. In the surroundings, severe inflammatory cell infiltration was seen with neutrophils and plasma cells. The number of TRAP-positive cells (osteoclast-like cells; multinucleated giant cells) was very small compared to that at 2 w e e k s a f t e r i m p l a n t Table 1) . Serum PTH and urinary DPD/Cre were significantly increased (p<0.05) ( Table 2) .
Changes in biomarkers of

Evaluation of bone density
In Group 1, bone density significantly increased as time progressed from 1, 2 and 4 weeks after implant placement ( Figure  2a) . However, no statistical difference in density was observed between Group 1 and Group 2 (control group) at any time point. In Group 3, bone density significantly decreased as the duration of bisphosphonate use increased (Figure 2b) .
Evaluation of light microscopy images
Group 2 had a larger amount of bone in the peri-implant area compared with Group 1 at 1, 2 and 8 weeks after implant placement (Figures 3a, b) . A similar tendency was observed at 2 weeks after implant placement but there was no significant difference between the groups. Group 1 had a larger amount of bone in the peri-implant area compared with Group 2 at 4 weeks after implant placement (Figures 4a and b) . As mentioned previously, Group 2 had a larger amount of peri-implant bone compared with Group 1 at 8 weeks after implant placement (Figures 5a and b) . Sequestrum formation was observed in tissue sections of Group 1 at 8 weeks after implant placement ( Figure   6 ). In tissue sections of Group 3, the areas between threads were filled with bone at all time points (Figure 7) .
Evaluation of lacunae without osteocytes
Group 1 had a significantly higher proportion of lacunae without osteocytes compared with Group 2 at all time points of 1, 2, 4, and 8 weeks after implant placement (Figure 8a ). In Group 3, the proportion of these lacunae increased significantly from one to two weeks after the start of bisphosphonate administration.
There were significantly higher proportions at 4 weeks and 8 weeks after the start of administration compared with 1 week after the start (Figure 8b ). 
Evaluation of TRAP-stained tissue specimens
Discussion
Implant treatment has already become an important prosthodontic treatment option for missing teeth. It has become widely used as a general treatment method. Implant treatment is often performed on elderly patients who are not necessarily in good health. Osteoporosis is a disease that is often seen in elderly individuals, particularly women. It is known that the risk for bone fracture becomes high as the disease progresses. Osteoporosis itself is not considered a risk factor in implant treatment [15] [16] [17] .
Bisphosphonates are drugs widely used to treat systemic bone diseases in clinical practice. However, they have potential side effects such as inflammation and osteonecrosis of the jaw after surgical treatment. Thus, there are discussions on the pros and cons of implant treatment in bisphosphonate users. Bisphosphonates have a high affinity for hydroxyapatite of bone tissue and are bone resorption inhibitors that suppress osteoclast activity 18) . They have been used widely as a first-line drug for osteoporosis in the fields of general surgery and orthopedic surgery. Bisphosphonates are also used in diseases characterized by bone fragility such as bone metastasis and multiple myeloma 1 9-2 1) . P resently, oral bisphosphonates are mainly used for osteoporosis and injectable bisphosphonates for bone metastasis of malignant tumor. BRONJ was first reported by Marx and Wang et al. in 2003 5,6) , and this condition has subsequently gained much attention. In recent years, reports have increased on osteonecrosis of the jaw after dental surgery in bisphosphonate users 22, 23) . BRONJ occurs at a particularly high frequency in patients using injectable bisphosphonates such as zoledronate. Oral bisphosphonates such as aledronate had been considered to have a low risk [24] [25] [26] . However, osteonecrosis of the jaw has also been reported in patients using oral bisphosphonates for osteoporosis 27, 22) . The pathogenesis is unknown, and there have been only a small number of reports on histological changes. Yarom et al. conducted a survey on BRONJ patients and found that 8.9% of these patients were oral bisphosphonate users 28) . Thus, one cannot ignore the occurrence of BRONJ due to oral bisphosphonate use.
Our study used an animal experimental model. In one group of rats, implants were placed following bisphosphonate administration after implant placement. In another group of rats, bisphosphonate was administered after osseointegration was achieved. The response of peri-implant tissue was evaluated histologically in both groups.
In blood tests and urinalysis, serum concentrations of ALP, 25(OH)D, PTH and DPD/Cre were significantly changed after 3 weeks of a vitamin D-deficient diet compared to before the diet. Thus, it was speculated that bone metabolism would change from a continued vitamin D-deficient diet.
In the evaluation of bone density using CT, peri-implant bone density of Group 1 increased significantly as time progressed after implant placement. There was no significant difference in bone density between Group 1 and Group 2 (control group). This result is consistent with that of Morinaga et al. 29) . who studied normal rats. In our study, detailed examination was performed on lacunae in bone tissue using a light microscope. In peri-implant bone, the proportion of lacunae without osteocytes was significantly higher in Group 1 than in Group 2. This finding suggests that bisphosphonates might have only a small effect on peri-implant bone density during osseointegration after implant placement. However, bisphosphonates can increase the areas of necrosis because decalcified bone tissue is not normal. According to the definition of BRONJ established by the American Association of Oral and Maxillofacial Surgeons, patients with this condition have the following characteristics: a history of treatment with bisphosphonate, no history of radiation treatment to the jaws, and persistent exposed necrotic bone. In our animal model, no exposed necrotic bone was observed. However, Group 1 had a significantly higher proportion of lacunae without osteocytes in the bone tissue compared to Group 2. Thus, osteonecrosis related to bisphosphonate use was observed.
In the evaluation of bone density, Group 1 showed increasing peri-implant bone density over time but Group 3 showed decreasing density over time. Both groups showed an increasing proportion of lacunae without osteocytes over time.
Group 1 showed a large number of TRAP-positive cells in the early stages after the start of bisphosphonate administration.
However, the number decreased as the duration of administration increased. In addition, cells became flattened. Similar findings were obtained from Group 3, and it was suspected that the activity of TRAP-positive cells decreased and their functions were inhibited. Therefore, our results suggest that bisphosphonate affects the activity of osteoclasts that accumulate in the jaw, regardless of whether bisphosphonate is administered before or after implant placement. Thus, there are concerns of negative effects on implant prognosis even after osseointegration is achieved. These effects include osteonecrosis in the peri-implant area, decreased bone density, and changes in TRAP-positive cells.
In conclution, our study examined the effects of bisphosphonate administration in rats before and after implant placement. The evaluation was performed on H&E-stained sections and TRAPstained sections which were examined under a light microscope.
Lacunae without osteocytes in peri-implant bone and osteonecrosis were observed in Group 1 with bisphosphonate administration starting before implant placement. This histological result suggests the need to exercise caution in using implant treatment on patients taking bisphosphonates. In Group 3 with bisphosphonate administration after osseointegration, peri-implant bone density decreased over time and the number of lacunae without osteocytes increased. This result suggests the need for caution in administering bisphosphonates in patients after implant placement.
